Viamet Pharma raises $60 mln

Viamet Pharmaceuticals Holdings said Tuesday it closed a $60 million Series D financing provided by Brandon Point Industries Ltd. working with Woodford Investment Management. Current investors includes Novartis Venture Fund, Lilly Ventures, Hatteras Venture Partners, Intersouth Partners, Lurie Holdings and Astellas Venture Management. Durham, N.C.-based Viamet Pharma develops antifungal agents using a metalloenzyme medicinal chemistry platform.

North AmericaUSBriefs